Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

November 30, 2027

Conditions

Infectious DiseasePharmacology

Interventions

DRUG

favipiravir

Light yellow, film-coated tablet, each containing 200 mg of favipiravir

DRUG

Placebo

Light yellow, film-coated tablet

Trial Locations (1)

RECRUITING

University Hospital Bichat - Claude Bernard, Paris

All Listed Sponsors

collaborator

FUJIFILM Toyama Chemical Co., Ltd.

INDUSTRY

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV